Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Edyta Szewczyk, Michaela Dümig, Thomas Hartmann, Basem M. Jaber, Patrick Olbermann, Joachim Morschhäuser, and Sven
Krappmann2011
12)
n/a
-
v
B.M. Nitsche , A.F.J. Ram , V. Meyer , J.R. Wortman
2011
11)
n/a
-
v
Alexandre Souvorov, Boris Kiryutin, Vyacheslav Chetvernin,
Barbara Robbertse, Leonid Zaslavsky, Tatiana Tatusova.,2011
10)
n/a
-
v
Colin P. De Souza, 1Shahr B. Hashmi, 1Aysha H. Osmani, 2Carol S. Ringelberg,
2Jay C. Dunlap and 1Stephen A. Osmani.2011
NULL
n/a
-
v
Mikael R. Andersen1, Jakob B. Nielsen1,
Mia Zachariassen1, Tilde J. Hansen1, Kristian F. Nielsen1, and Uffe H. Mortensen12011
NULL
n/a
-
v
Hideaki Koike , Junichiro Marui ,
1 1
Noriko Yamane ,Sumiko Ohashi , Yasunobu Terabayashi ,Motoaki Sano , Shinichi Ohashi , Eiji Ohshima , Kuniharu Tachibana , Yoshitaka Higa , Marie
Nishimura , and Masayuki Machida2011
7)
n/a
-
v
Vinita Joardar, Suman Pakala, Jessica Hostetler, Suchitra
Pakala, Natalie Fedorova and William Nierman2011
6)
n/a
-
v
Kuo, Alan , Asaf Salamov , Scott Baker , and Igor Grigoriev
2011
3)
n/a
-
v
Takanori Nomura , Tomoaki Fujimura , Kenta Oda , Kazuhiro
Iwashita2011
2)
n/a